-
公开(公告)号：US20240335517A1
公开(公告)日：2024-10-10
申请号：US18493262
申请日：2023-10-24
Applicant: VITAMERICA UG (HAFTUNGSBESCHRANKT)
Inventor： Daniel Henry WYROBNIK , Isaac Harry WYROBNIK
IPC: A61K38/52 , A23L29/00 , A23L33/10 , A23L33/18 , A23L33/20 , A61K9/48 , A61K38/44 , A61K38/54 , A61P1/00
CPC classification number: A61K38/52 , A23L29/06 , A23L33/10 , A23L33/18 , A23L33/20 , A61K9/485 , A61K9/4858 , A61K38/44 , A61K38/54 , A61P1/00 , C12Y101/99011 , C12Y302/0102 , C12Y302/01026 , C12Y503/01005 , A23V2002/00 , A61K2300/00
Abstract: There is provided a method for treating or reducing the effects of fructose intolerance and health problems associated with excessive fructose intake by administration of glucose isomerase. Other embodiments are also disclosed.
-
公开(公告)号：US20240245761A1
公开(公告)日：2024-07-25
申请号：US18583069
申请日：2024-02-21
Applicant: Curemark, LLC
Inventor： Joan M. Fallon , Matthew F. Heil , James Szigethy , James J. Fallon
CPC classification number: A61K38/54 , A61K38/465 , A61K38/47 , A61K38/48
Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of Celiac disease. Also described herein is a method for treating a subject with Celiac disease using digestive enzymes and their derivatives to alleviate the symptoms of Celiac disease. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of Celiac disease.
-
公开(公告)号：US11950569B2
公开(公告)日：2024-04-09
申请号：US16611658
申请日：2018-05-08
Applicant: Novozymes A/S
Inventor： Niels Henrik Soerensen
CPC classification number: A01K15/026 , A23K50/40 , A61K38/54
Abstract: The invention provides an animal chew toy comprising a dental care composition, wherein the dental care composition comprises at least one peroxidase and at least one oxidase.
-
4.发明申请公开(公告)号：US20190231855A1
公开(公告)日：2019-08-01
申请号：US16231195
申请日：2018-12-21
Applicant: Baxalta Incorporated , Baxalta GmbH
Inventor： Michael Dockal , Sabine Knappe , Susanne Till , Peter Leopold Turecek , Friedrich Scheiflinger
CPC classification number: A61K38/4833 , A61K38/4846 , A61K38/54 , C12Y304/21005 , C12Y304/21006
Abstract: Disclosed herein are compositions and methods for improving hemostasis in the treatment of bleeding disorders and reversal of anticoagulant activity. Effective ratios of prothrombin (FII) and activated factor X (FXa) for the treatment of bleeding disorders that are as efficacious as FEIBA®, but require a lower concentration of FII are described herein.
-
公开(公告)号：US20190183990A1
公开(公告)日：2019-06-20
申请号：US16281908
申请日：2019-02-21
Applicant: Curemark, LLC
Inventor： Joan M. Fallon , Matthew Heil , James Szigethy , James Fallon
CPC classification number: A61K38/54 , A61K9/0053 , A61K38/465 , A61K38/47 , A61K38/48 , A61K45/06 , A61P25/00 , C12Y301/01 , C12Y302/01 , C12Y304/00
Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
-
Patent Agency Ranking
公开(公告)号：US20180161409A1
公开(公告)日：2018-06-14
申请号：US15889917
申请日：2018-02-06
Applicant: Curemark, LLC
Inventor： Joan Fallon
IPC: A61K38/54 , A61K36/185 , A61K38/47 , A61K38/48 , A61K38/46
CPC classification number: A61K38/54 , A61K36/185 , A61K38/465 , A61K38/47 , A61K38/48 , A61K38/4826 , A61K38/4873 , C12Y301/00 , C12Y302/01 , C12Y304/00 , C12Y304/21001 , C12Y304/21004 , C12Y304/22002 , A61K2300/00
Abstract: A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent are disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker, to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed.
-
公开(公告)号：US20180036393A1
公开(公告)日：2018-02-08
申请号：US15717396
申请日：2017-09-27
Applicant: AbbVie Inc.
Inventor： Martin Babcock , Cynthia Burnell , Daniel Crandall , John Dete , Mark Hess , Shannon Hertzler , Vikram Kalthod , William Riordan , Houston Sanders
CPC classification number: A61K38/54 , A61K38/465 , A61K41/0009 , A61L2/08 , C12N9/20 , C12N9/94 , C12N13/00 , C12Y301/01003
Abstract: The present invention pertains to an enzyme preparation obtained from e-beam irradiated animal tissue, such as porcine pancreas. The present invention also pertains to methods for making such enzyme preparations, pharmaceutical compositions comprising such enzymes preparations, and methods for using such pharmaceutical compositions and enzyme preparations.
-
公开(公告)号：US20170368152A1
公开(公告)日：2017-12-28
申请号：US15698820
申请日：2017-09-08
Applicant: Thea Fournier
Inventor： Thea Fournier
CPC classification number: A61K38/4826 , A61K38/465 , A61K38/47 , A61K38/54 , C12N9/00 , C12N9/16 , C12N9/2402 , C12N9/6427 , C12Y301/03 , C12Y302/01 , C12Y302/01026 , C12Y302/01108 , C12Y304/21001
Abstract: Disclosed is a formulation of the following enzymes: Beta Glucanase, Chymotrypsin, Phytase, Lactase, and Invertase, which has been found to be effective in treating salicylate intolerant people, and causing a significant improvement in a wide variety of pathologies and symptoms, including, but not limited to: acid reflux disease, stuttering, migraines, ADHD, behavioral deficits, Tourettes disease, seizures, autism (ASD), atrial fibrillation, anxiety, depression, joint pain, cognitive and perceptual disorders, respiratory difficulties and non-diabetic neuropathy. The formulation is also for treating or reducing intolerance of gluten, corn or soy.
-
公开(公告)号：US20170189501A1
公开(公告)日：2017-07-06
申请号：US15265415
申请日：2016-09-14
Applicant: CUREMARK, LLC
Inventor： Joan M. Fallon , Matthew Heil , James Szigethy , James Fallon
CPC classification number: A61K38/54 , A61K9/0053 , A61K38/465 , A61K38/47 , A61K38/48 , A61K45/06 , A61P25/00 , C12Y301/01 , C12Y302/01 , C12Y304/00
Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
-
10.发明授权公开(公告)号：US09682131B2
公开(公告)日：2017-06-20
申请号：US14757363
申请日：2015-12-22
Applicant: Kilmer S. McCully
Inventor： Kilmer S. McCully
IPC: A61K31/381 , A61K38/48 , A61K38/54 , A61K8/67 , A61K31/16 , A61K38/46 , A61K38/47 , A61K31/07 , A61K45/06 , A61K35/39 , A61K31/00
CPC classification number: A61K38/54 , A61K8/66 , A61K8/671 , A61K31/00 , A61K31/07 , A61K31/16 , A61K35/39 , A61K38/465 , A61K38/47 , A61K38/4826 , A61K45/06 , A61Q19/08 , C12Y301/01003 , C12Y302/01001 , C12Y302/01002 , C12Y304/21004 , A61K2300/00
Abstract: A process for the endogenic catabolism of homocysteine and the control of homocysteine levels for treating disease and the degenerative diseases of aging is provided along with pharmaceutical compositions having thioretinamide, retinol or combinations thereof in combination with an enzyme or a pro-enzyme. The process includes the catabolism of homocysteine thiolactone in cells and tissues by catalyzing the reaction of homocysteine thiolactone with an enzyme-bound retinoic acid to increase the bioavailability of thioretinamide in diseased and aged cells and tissue.
-
-
-
-
-
-
-
-
-
Search Results
277
records
(took 0.03 seconds)
